10 results on '"Srivastava, Saurabh"'
Search Results
2. Drug Delivery Strategies in Parkinson’s Disease
- Author
-
Singh, Gurpreet, Sikder, Anupama, Singh, Shashi Bala, Srivastava, Saurabh, Khatri, Dharmendra Kumar, Mishra, Awanish, editor, and Kulhari, Hitesh, editor
- Published
- 2023
- Full Text
- View/download PDF
3. Pathological and Therapeutic Advances in Parkinson's Disease: Mitochondria in the Interplay.
- Author
-
Naren, Padmashri, Cholkar, Anjali, Kamble, Suchita, Khan, Sabiya Samim, Srivastava, Saurabh, Madan, Jitender, Mehra, Neelesh, Tiwari, Vinod, Singh, Shashi Bala, and Khatri, Dharmendra Kumar
- Subjects
PARKINSON'S disease ,MITOCHONDRIAL DNA ,MITOCHONDRIAL pathology ,SUBSTANTIA nigra ,BIOENERGETICS ,OXIDATIVE stress - Abstract
Parkinson's disease (PD) is the second most common neurodegenerative illness majorly affecting the population between the ages of 55 to 65 years. Progressive dopaminergic neuronal loss and the collective assemblage of misfolded alpha-synuclein in the substantia nigra, remain notable neuro-pathological hallmarks of the disease. Multitudes of mechanistic pathways have been proposed in attempts to unravel the pathogenesis of PD but still, it remains elusive. The convergence of PD pathology is found in organelle dysfunction where mitochondria remain a major contributor. Mitochondrial processes like bioenergetics, mitochondrial dynamics, and mitophagy are under strict regulation by the mitochondrial genome and nuclear genome. These processes aggravate neurodegenerative activities upon alteration through neuroinflammation, oxidative damage, apoptosis, and proteostatic stress. Therefore, the mitochondria have grabbed a central position in the patho-mechanistic exploration of neurodegenerative diseases like PD. The management of PD remains a challenge to physicians to date, due to the variable therapeutic response of patients and the limitation of conventional chemical agents which only offer symptomatic relief with minimal to no disease-modifying effect. This review describes the patho-mechanistic pathways involved in PD not only limited to protein dyshomeostasis and oxidative stress, but explicit attention has been drawn to exploring mechanisms like organelle dysfunction, primarily mitochondria and mitochondrial genome influence, while delineating the newer exploratory targets such as GBA1, GLP, LRRK2, and miRNAs and therapeutic agents targeting them. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Understanding the Involvement of microRNAs in Mitochondrial Dysfunction and Their Role as Potential Biomarkers and Therapeutic Targets in Parkinson's Disease.
- Author
-
Tryphena, Kamatham Pushpa, Anuradha, Urati, Kumar, Rohith, Rajan, Shruti, Srivastava, Saurabh, Singh, Shashi Bala, and Khatri, Dharmendra Kumar
- Subjects
PARKINSON'S disease ,MITOCHONDRIAL pathology ,MOVEMENT disorders ,DRUG target ,MITOCHONDRIA ,GENETIC regulation ,MICRORNA - Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disease, affecting the elderly worldwide and causing significant movement impairments. The goal of PD treatment is to restore dopamine levels in the striatum and regulate movement symptoms. The lack of specific biomarkers for early diagnosis, as well as medication aimed at addressing the pathogenic mechanisms to decelerate the progression of dopaminergic neurodegeneration, are key roadblocks in the management of PD. Various pathogenic processes have been identified to be involved in the progression of PD, with mitochondrial dysfunction being a major contributor to the disease's pathogenesis. The regulation of mitochondrial functions is influenced by a variety of factors, including epigenetics. microRNAs (miRNAs) are epigenetic modulators involved in the regulation of gene expression and regulate a variety of proteins that essential for proper mitochondrial functioning. They are found to be dysregulated in PD, as evidenced by biological samples from PD patients and in vitro and in vivo research. In this article, we attempt to provide an overview of several miRNAs linked to mitochondrial dysfunction and their potential as diagnostic biomarkers and therapeutic targets in PD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. GSK-3β: An exuberating neuroinflammatory mediator in Parkinson's disease.
- Author
-
Samim Khan, Sabiya, Janrao, Sushmita, Srivastava, Saurabh, Bala Singh, Shashi, Vora, Lalitkumar, and Kumar Khatri, Dharmendra
- Subjects
- *
PARKINSON'S disease , *POST-translational modification , *ALZHEIMER'S disease , *INFLAMMATORY mediators , *NLRP3 protein , *TRANSCRIPTION factors , *NEUROGLIA - Abstract
[Display omitted] Neuroinflammation is a critical degradative condition affecting neurons in the brain. Progressive neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease (PD) have been strongly linked to neuroinflammation. The trigger point for inflammatory conditions in the cells and body is the physiological immune system. The immune response mediated by glial cells and astrocytes can rectify the physiological alterations occurring in the cell for the time being but prolonged activation leads to pathological progression. The proteins mediating such an inflammatory response, as per the available literature, are undoubtedly GSK-3β, NLRP3, TNF, PPARγ, and NF-κB, along with a few other mediatory proteins. NLRP3 inflammasome is undeniably a principal instigator of the neuroinflammatory response, but the regulatory pathways controlling its activation are still unclear, besides less clarity for the interplay between different inflammatory proteins. Recent reports have suggested the involvement of GSK-3β in regulating NLRP3 activation, but the exact mechanistic pathway remains vague. In the current review, we attempt to provide an elaborate description of crosstalk between inflammatory markers and GSK-3β mediated neuroinflammation progression, linking it to regulatory transcription factors and posttranslational modification of proteins. The recent clinical therapeutic advances targeting these proteins are also discussed in parallel to provide a comprehensive view of the progress made in PD management and lacunas still existing in the field. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Dimethyl fumarate ameliorates parkinsonian pathology by modulating autophagy and apoptosis via Nrf2-TIGAR-LAMP2/Cathepsin D axis.
- Author
-
Khot, Mayuri, Sood, Anika, Tryphena, Kamatham Pushpa, Pinjala, Poojitha, Srivastava, Saurabh, Singh, Shashi Bala, and Khatri, Dharmendra Kumar
- Subjects
- *
DIMETHYL fumarate , *CATHEPSIN D , *AUTOPHAGY , *APOPTOSIS , *PARKINSON'S disease , *PROTEOLYSIS , *CELL death - Abstract
[Display omitted] • Autophagy clears defective organelle and misfolded proteins in the cell. • Autophagolysosome formation is impaired in Parkinson's disease (PD). • Dimethyl fumarate (DMF) improves autophagy via modulation of the Nrf2-TIGAR-LAMP2 axis. • DMF suppresses p53 and Cathepsin D expression which may inhibit dopaminergic neuronal apoptosis. • DMF treatment alleviated PD pathology in rotenone induced PD mice model. Mounting evidence suggests a role for oxidative stress and accumulation of dysfunctional organelle and misfolded proteins in PD. Autophagosomes mediate the clearance of these cytoplasmic proteins via delivery to lysosomes to form autophagolysosomes, followed by degradation of the protein by lysosomal enzymes. In PD, autophagolysosome accumulation occurs initiating a plethora of events resulting in neuronal death by apoptosis. This study evaluated the effect of Dimethylfumarate (DMF), an Nrf2 activator in the rotenone-induced mouse PD model. In PD mice, there was decreased expression of LAMP2 and LC3, which resulted in inhibition of autophagic flux and increased expression of cathepsin D, which mediated apoptosis. The role of Nrf2 activation in alleviating oxidative stress is well known. Our study elucidated the novel mechanism underlying the neuroprotective effect of DMF. The loss of dopaminergic neurons induced by rotenone was lessened to a significant extent by pre-treatment with DMF. DMF promoted autophagosome formation and inhibited apoptosis by removing the inhibitory effect of p53 on TIGAR. TIGAR expression upregulated LAMP2 expression and downregulated Cathepsin D, promoting autophagy and inhibiting apoptosis. Thus, it was proved that DMF confers neuroprotection against rotenone-induced dopaminergic neurodegeneration and could be used as a potential therapeutic agent for PD and its progression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Understanding the involvement of innate immunity and the Nrf2-NLRP3 axis on mitochondrial health in Parkinson's disease.
- Author
-
Rajan, Shruti, Tryphena, Kamatham Pushpa, Khan, Sabiya, Vora, Lalitkumar, Srivastava, Saurabh, Singh, Shashi Bala, and Khatri, Dharmendra Kumar
- Subjects
- *
NUCLEAR factor E2 related factor , *PARKINSON'S disease , *NATURAL immunity , *MITOCHONDRIA - Abstract
Parkinson's disease (PD), a multifactorial movement disorder, is interlinked with numerous molecular pathways, including neuroinflammation, which is a critical factor in the development and progression of PD. Microglia play a central role in driving neuroinflammation through activation and overexpression of the M1 phenotype, which has a significant impact on mitochondria. Multiple regulators converge together, and among these, the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasomes have been implicated in transmitting inflammatory and deleterious components to the mitochondria. Nuclear factor erythroid 2–related factor 2 (Nrf2) regulates the NLRP3 inflammasome and acts as the saviour of the mitochondria. Together, the NLRP3-Nrf2 axis functions in regulating mitochondrial function in the case of PD. It regulates fundamental processes such as oxidative stress, mitochondrial respiratory function, and mitochondrial dynamics. In this review, we discuss the contributions that a variety of miRNAs make to the regulation of the NLRP3 inflammasome and Nrf2, which can be used to target this important axis and contribute to the preservation of mitochondrial integrity. This axis may prove to be a crucial target for extending the lives of Parkinson's patients by deferring neuroinflammatory damage to mitochondria. • Activated microglia release the NLRP3 inflammasome, resulting in neuroinflammation in PD. • NLRP3 inflammasome causes mitochondrial dysfunction. • Nrf2 is a key antioxidant molecule that increases the survival of mitochondria. • NLRP3-Nrf2 functions through crosstalk and function in opposing manners in PD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Inter and intracellular mitochondrial transfer: Future of mitochondrial transplant therapy in Parkinson's disease.
- Author
-
Jain, Rachit, Begum, Nusrat, Tryphena, Kamatham Pushpa, Singh, Shashi Bala, Srivastava, Saurabh, Rai, Sachchida Nand, Vamanu, Emanuel, and Khatri, Dharmendra Kumar
- Subjects
- *
PARKINSON'S disease , *MITOCHONDRIA , *ADENOSINE triphosphate , *DOPAMINERGIC neurons , *EXTRACELLULAR vesicles - Abstract
Parkinson's disease (PD) is marked by the gradual degeneration of dopaminergic neurons and the intracellular build-up of Lewy bodies rich in α-synuclein protein. This impairs various aspects of the mitochondria including the generation of ROS, biogenesis, dynamics, mitophagy etc. Mitochondrial dynamics are regulated through the inter and intracellular movement which impairs mitochondrial trafficking within and between cells. This inter and intracellular mitochondrial movement plays a significant role in maintaining neuronal dynamics in terms of energy and growth. Kinesin, dynein, myosin, Mitochondrial rho GTPase (Miro), and TRAK facilitate the retrograde and anterograde movement of mitochondria. Enzymes such as Kinases along with Calcium (Ca2+), Adenosine triphosphate (ATP) and the genes PINK1 and Parkin are also involved. Extracellular vesicles, gap junctions, and tunneling nanotubes control intercellular movement. The knowledge and understanding of these proteins, enzymes, molecules, and movements have led to the development of mitochondrial transplant as a therapeutic approach for various disorders involving mitochondrial dysfunction such as stroke, ischemia and PD. A better understanding of these pathways plays a crucial role in establishing extracellular mitochondrial transplant therapy for reverting the pathology of PD. Currently, techniques such as mitochondrial coculture, mitopunch and mitoception are being utilized in the pre-clinical stages and should be further explored for translational value. This review highlights how intercellular and intracellular mitochondrial dynamics are affected during mitochondrial dysfunction in PD. The field of mitochondrial transplant therapy in PD is underlined in particular due to recent developments and the potential that it holds in the near future. [Display omitted] • Transport of mitochondria across the neurons serve as critical mediator for cellular fitness and health. • Mitophagy and biogenesis replenish the mitochondrial pool, sustaining the cell's mitochondrial repertoire. • Mitochondrial dysfunctions play pivotal role in neurodegenerative disorders including PD. • Inter and intracellular transport of mitochondria is governed by various molecular signaling pathways. • Mitochondrial Transplantation therapy could be a potentially unique method for enhancing clinical impact in PD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Proteostasis in Parkinson's disease: Recent development and possible implication in diagnosis and therapeutics.
- Author
-
Kulkarni, Amrita, Preeti, Kumari, Tryphena, Kamatham Pushpa, Srivastava, Saurabh, Singh, Shashi Bala, and Khatri, Dharmendra Kumar
- Subjects
- *
PARKINSON'S disease , *UNFOLDED protein response , *X chromosome , *PROTEOLYSIS , *ALPHA-synuclein , *UBIQUITIN , *THERAPEUTICS - Abstract
The protein dyshomeostasis is identified as the hallmark of many age-related neurodegenerative disorders including Parkinson's disease (PD). The diseased brain shows the deposition of Lewy bodies composed of α-synuclein protein aggregates. Functional proteostasis is characterized by the well-coordinated signaling network constituting unfolded protein response (UPR), the ubiquitin-proteasome system (UPS), and the autophagy-lysosome pathway (ALP). These networks ensure proper synthesis, folding, confirmation, and degradation of protein i.e., α-synuclein protein in PD. The proper functioning the of intricately woven proteostasis network is quite resilient to sustain under the influence of stressors. The synuclein protein turnover is hugely influenced by the autosomal dominant, recessive, and X-linked mutational changes of a gene involved in UPR, UPS, and ALP. The methylation, acetylation-related epigenetic modifications of DNA and histone proteins along with microRNA-mediated transcriptional changes also lead to extensive proteostasis dysregulation. The result of defective proteostasis is the deposition of many proteins which start appearing in the biofluids and can be identified as potential biomarkers for early diagnosis of PD. The therapeutic intervention targeted at different strata of proteostasis machinery holds great possibilities for delaying the age-related accumulation of pathological hallmarks. • Regulation of neuronal α-synuclein turnover by Unfolded Protein Response, Ubiquitin Proteasome System, and Autophagy. • LRRK2, UCHL1, VPS35, DNAJC13, DJ-1, ATP13A2, FBXO7, VPS13C mutations disrupt proteostasis affecting α-synuclein clearance. • Epigenetic influence on LAMP2A, HSP 70, SNCA, ATG-5, PINK-1 causes dysfunctional proteostasis in PD. • NEAT1 , PROSAAS and 7B2, BECLIN-1, ATG-5, AIMP2, Ox DJ-1, RAB, ATP13A2 as biomarkers for early PD diagnosis. • Drug therapies targeting proteostasis and PD-associated proteome stability in preclinical and clinical settings. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. NLRP3 inflammasomes: A potential target to improve mitochondrial biogenesis in Parkinson's disease.
- Author
-
Khot, Mayuri, Sood, Anika, Tryphena, Kamatham Pushpa, Khan, Sabiya, Srivastava, Saurabh, Singh, Shashi Bala, and Khatri, Dharmendra Kumar
- Subjects
- *
PARKINSON'S disease , *NLRP3 protein , *MITOCHONDRIA , *INFLAMMASOMES , *MITOCHONDRIAL DNA , *INTERLEUKIN-1 receptors , *REACTIVE oxygen species - Abstract
Parkinson's disease (PD) is a common neurodegenerative condition for which no approved treatment exists to prevent collective neuronal death. There is ample evidence that mitochondrial dysfunction, reactive oxygen species (ROS), and associated caspase activity underlie the pathology observed. Neurons rely on mitochondrial activity since they have such high energy consumption. Therefore, it is not surprising that mitochondrial alterations favour neuronal degeneration. In particular, mitochondrial dysregulation contributes to PD, based on the observation that mitochondrial toxins can cause parkinsonism in humans and animal models. Also, it is known that inflammatory cytokine-mediated neuroinflammation is the key pathogenic mechanism in neuronal loss. In recent years, the research has focussed on mitochondria being the platform for nucleotide-binding oligomerization domain-like receptors 3 (NLRP3) inflammasome activation. Mitochondrial dysfunction and NLRP3 activation are emerging as critical players in inducing and sustaining neuroinflammation. Moreover, mitochondrial-derived ROS and mitochondrial DNA (mtDNA) could serve as the priming signal for forming inflammasome complexes responsible for the activation, maturation, and release of pro-inflammatory cytokines, including interleukin-1(IL-1) and interleukin-18 (IL-18). The current review takes a more comprehensive approach to elucidating the link between mitochondrial dysfunction and aberrant NLRP3 activation in PD. In addition, we focus on some inhibitors of NLRP3 inflammatory pathways to alleviate the progression of PD. [Display omitted] • Mitochondrial biogenesis is emerging as an integral player in neurodegenerative diseases like Parkinson's Disease. • NLRP3 inflammasome activation is crucial for neuroinflammation. • Mitochondrial reactive oxygen species and oxidized mitochondrial DNA mediate NLRP3 inflammasome activation. • Inhibition of NLRP3 inflammasome can mitigate the harmful effects of mitochondrial dysfunction. • NLRP3 inflammasome inhibitors could ameliorate mitochondrial dysfunction and neuroinflammation in Parkinson's Disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.